Европейский союз - мальтийский - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - orlistat - obeżità - preparazzjonijiet ta 'kontra l-ossessjoni, esklużi prodotti tad-dieta - xenical hija indikata flimkien mal-mildly hypocaloric dieta għat-trattament tal-pazjenti obese mal-korp massa indiċi (bmi) ikbar jew ugwali għal 30 kg/m2, jew tas-saħħa, l-pazjenti (bmi > 28 kg/m2) mal-fatturi ta ' riskju assoċjati. kura b'orlistat għandha titwaqqaf wara 12-il ġimgħa jekk il-pazjenti ma jkunux tilfu tal-inqas 5% tal-piż tal-ġisem kif imkejjel fil-bidu tat-terapija.

Европейский союз - мальтийский - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - ceftolozane sulfate, tazobactam sodium - infezzjonijiet batteriċi - antibatteriċi għal użu sistemiku, - zerbaxa is indicated for the treatment of the following infections in adults:complicated intra abdominal infections;acute pyelonephritis;complicated urinary tract infections;hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap). għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi.

Европейский союз - мальтийский - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - adalimumab - hidradenitis suppurativa; arthritis, psoriatic; psoriasis; crohn disease; arthritis, juvenile rheumatoid; uveitis; arthritis, rheumatoid; colitis, ulcerative; spondylitis, ankylosing - immunosoppressanti - jekk jogħġbok irreferi għas-sezzjoni 4. 1 tas-sommarju tal-karatteristiċi tal-prodott fid-dokument ta 'informazzjoni tal-prodott.

Европейский союз - мальтийский - EMA (European Medicines Agency)

astrazeneca ab - andexanet alfa - relatati mal-mediċina l-effetti sekondarji u l-reazzjonijiet avversi - il-prodotti terapewtiċi l-oħra kollha - għall-pazjenti adulti kkurati b'dirett fattur xa (fxa) inibitur tal - (apixaban jew rivaroxaban) meta t-treġġigħ lura ta 'l-antikoagulazzjoni hu meħtieġ minħabba l-periklu għall-ħajja jew mhux ikkontrollat ta' fsada.

Европейский союз - мальтийский - EMA (European Medicines Agency)

evolus pharma b.v. - botulinum toxin tip a - xjuħija tal-Ġilda - oħra tal-rilassanti tal-muskoli, b'mod periferiku aġenti li jaġixxi - temporanja it-titjib fid-dehra tal moderat għal sever tal-linji vertikali bejn l-għajnejn dehru fil-massimu frown (glabellar-linji), meta l-severità ta 'l hawn fuq tal-wiċċ tal-linji għandha parti importanti-impatt psikoloġiku fl-adulti ta' taħt il-65 sena.

Европейский союз - мальтийский - EMA (European Medicines Agency)

genzyme europe bv - mipomersen sodium - iperkolesterolemija - sistema kardjovaskulari - it-trattament tal-kolesterol u l-iperkolesterolimja,.

Европейский союз - мальтийский - EMA (European Medicines Agency)

wyeth europa ltd - gemtuzumab ozogamicin - lewkimja, mijelojda, akuta - aġenti antineoplastiċi - mill-ġdid tal-kura ta 'induzzjoni ta cd33-pożittivi aml f'pazjenti adulti fl-ewwel rikaduta li mhumiex kandidati għall-oħra intensiv mill-ġdid l-induzzjoni ta' kimoterapija (e. doża għolja ara-c) u tissodisfax mill-inqas wieħed mill-kriterji li ġejjin: t-tul ta'l-ewwel remissjoni 60 sena.

Европейский союз - мальтийский - EMA (European Medicines Agency)

biocryst ireland limited - berotralstat dihydrochloride - angioedemas, ereditarji - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.

Европейский союз - мальтийский - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tip 2 - drogi użati fid-dijabete - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , terapija ta 'kumbinazzjoni tripla) bħala żieda mad-dieta u l-eżerċizzju f'pazjenti mhux ikkontrollati adegwatament fuq id-doża massima ttollerata ta' metformin u sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Европейский союз - мальтийский - EMA (European Medicines Agency)

merck europe b.v. - tepotinib hydrochloride monohydrate - karċinoma, pulmun mhux taċ-Ċellula Żgħira - aġenti antineoplastiċi - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.